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The last decade has seen substantial advances in the development of gene therapy strategies and vector technology for the treatment
of a diverse number of diseases, with a view to translating the successes observed in animal models into the clinic. Perhaps the
overwhelming drive for the increase in vascular gene transfer studies is the current lack of successful long-term pharmacological
treatments for complex cardiovascular diseases. The increase in cardiovascular disease to epidemic proportions has also led many
to conclude that drug therapy may have reached a plateau in its eﬃcacy and that gene therapy may represent a realistic solution to a
long-term problem. Here, we discuss gene delivery approaches and target diseases.
INTRODUCTION
Gene transfer enables the overexpression of candidate
therapeutic genes either locally or systemically. Cardio-
vascular disease targets under investigation include ther-
apeutic angiogenesis in ischaemic myocardium and limb
muscles, treatment of hypertension, vascular bypass graft
occlusion, and prevention of postangioplasty restenosis
(Table 1). Cardiovascular diseases are diverse and as such
have unique traits requiring precise tailoring of gene ther-
apystrategiestoaparticulardisease.Thosefeatureswhich
may vary include mode of delivery, type of vector, length
of gene expression, and target tissue. Unlike other inher-
ited genetic defects which may require more long-term
gene transfer, transient, nonintegrative gene expression
has been shown to be suﬃcient to promote neovascular-
izationinthecaseofangiogenesis[1].Thismayalsoapply
to antiproliferative strategies for the prevention of neoin-
tima formation postangioplasty, for the prevention of in-
stent restenosis, or for gene therapy of coronary artery by-
pass graft failure [2, 3]. However, complex diseases with
substantial polygenic inﬂuences such as essential hyper-
tension will require sustained gene overexpression.
STRATEGIES FOR GENE DELIVERY
The breadth of applications for vascular gene ther-
apy is accompanied by a need to deliver the therapeutic
gene(s) to diverse vascular cell types including vascular
smoothmuscle(SMC),endothelium,myocardium,ortis-
sues that inﬂuence lipid metabolism. Vector systems and
gene delivery technologies must therefore be developed
for individual applications. The four main modes of in-
troducing therapeutic genes into the vasculature are ex
vivogene transfer to vessel segments and gene delivery us-
ing cell-based, systemic, and local delivery approaches.
Exvivogenetherapy
Where appropriate, ex vivo genetic modiﬁcation of
vascular tissue is preferred as this allows the delivery of
therapeutic genes to the target tissue in a safe and eﬃcient
manner. This is the method of choice for gene therapy of
vein graft failure. During coronary artery bypass surgery
(CABG), there is direct access to the vein in the clinical
setting, enabling incubation and subsequent transduction
with the vector before grafting. In this way, systemic re-
lease of the vector is avoided therefore decreasing poten-
tial deleterious transgene expression at distal sites. Addi-
tionally, the immune system response to the virus is di-
minished, since at the time of grafting all excess virus has
been removed.
Cell-basedgeneticmodiﬁcation
Cell-based gene therapy involves the harvesting of
cells from patients, ex vivo transduction to express
therapeutic genes, and subsequent reimplantation of
genetically-modiﬁed autologous cells. There have been
very few studies of this kind. Perhaps the best example of
this approach is the ex vivo approach used by Grossman et
al [4] to treat familial hypercholesterolaemia. They trans-
duced hepatocytes with retroviruses expressing a wild-
type copy of low density lipoprotein receptor (LDL-R).
Upon reimplantation, a reduction in the total cholesterol
level from 671 to 608 was observed for one year [4]. De-
spite the partial success of this approach, there has been
little enthusiasm for this cell-based strategy. In a diﬀer-
entapproach,injuredratcarotidarterieswereseededwith2003:2 (2003) Gene Therapy for Cardiovascular Disease 139
Table 1. Gene therapy strategies for the treatment of cardiovascular diseases.
Disease Therapeutic approach Target
Atherosclerosis Antiatherogenic LCAT, apoAI, apoE mRNA
Vein graft failure, Diﬀusable/secreted gene products VEGF, FGF, eNOS, antithrombotic
ischaemia, thrombosis agents, SOD, heme oxygenase
Vein graft failure Inhibitors of smooth muscle cell p53, TIMPs, Rb, p21
migration/proliferation
Thrombosis Prevention of thrombus formation TFPI, tPA
Restenosis Suicide genes Tk
Hypertension Antisense oligonucleotides Angiotensinogen, AT1 receptor, ACE
Vein graft failure Decoys Soluble VCAM, E2F
Hypertension Reduction in blood pressure Kallikrein, ANP, eNOS, endothelin
SMCs overexpressing the tissue inhibitor of matrix metal-
loproteinase (TIMP)-1, a signiﬁcant decrease in neointi-
mal hyperplasia was observed conﬁrming that this tech-
nique can be used to exploit a biological eﬀect [5].
Localgenedeliveryinvivo
As many target vascular tissues are inaccessible by sys-
temic vector administration, such as the ischaemic my-
ocardium or atherosclerotic coronary arteries, local deliv-
ery devices have achieved substantial attention and de-
velopment as means of delivering vectors in a safe, se-
lective, and eﬃcient manner. Catheter design has rapidly
evolved since its ﬁrst attempts at arterial wall gene trans-
fer [6]. Delivery catheters can be used under X-ray ﬂu-
oroscopy guidance for gene delivery and by means of a
contrast medium, only the lumen of the vessel is vis-
ible. Development of this process using magnetic res-
onance imaging (MRI) will provide valuable informa-
tion on the vessel wall structure and interactions be-
tween genes and atherosclerotic lesions [7]. Another ex-
ample of localised vascular gene transfer is by the use of
stents [8]. Stents are commonly used devices that provide
as c a ﬀold structure to hold diseased arteries open. This
can be exploited as a medium through which to deliver
genes. Although stents have provided an eﬀective treat-
ment for stenotic saphenous aortocoronary bypass grafts,
procedure-related complications have been observed in
20% of cases [9]. A recent study in a pig model demon-
strated stable in vivo transgene expression in the vascula-
ture over a 4-week period from a ﬁbronectin-coated stent
platform seeded with green ﬂuorescent protein (GFP)
transduced autologous SMC [10]. However, adherence of
cells to stent surfaces under ﬂow conditions is particularly
poor with certain cell types such as endothelial cells [11].
Stents designed with a distal-embolic protection device in
conjunction with a covering of therapeutic genes could
be used to prevent adverse coronary events. A wide array
of mechanical devices for gene delivery have been investi-
gated for local gene therapy and include double balloon,
channel balloon, and hydrogel coated catheters, microp-
orous coated stents, microspheres, and nipple catheters
(for review see [12]).
Systemicgenedelivery
Following in vivo administration of viral vector sys-
tems, liver sequestration predominantly occurs, preclud-
ing eﬃcient vascular gene delivery through this route of
administration[13,14].Duetotheeﬃcientuptakeofsys-
temically administered vectors by the liver, cardiovascular
genetherapeuticstrategiesarelimitedforthismodeofde-
livery due to the inadequacies in vector technology. How-
ever,thelivercanbeusedtomodifylipidmetabolism[15]
or as a factory through which to ﬂood the bloodstream
with soluble therapeutic proteins. Systemic gene therapy
has been explored for the treatment of hypercholestero-
laemia and hypertension (for review see [16]). As an ex-
ample, systemic injection of adenovirus-apoE into the tail
vein of atherosclerotic apoE−/− mice caused an immediate
fall in plasma cholesterol levels and a sustained reduction
in atherosclerosis [15].
VECTORS FOR GENE THERAPY
Viralvectors
Successful gene therapy requires the fulﬁlment of sev-
eralcriteria,namely,theappropriatetherapeuticgeneand
most importantly a suitable vector for delivery and sub-
sequent eﬃcient expression of the transgene. The ideal
gene transfer vector should be nonpathogenic, eﬃciently
transduce target cells, and elicit a minimal immuno-
genic response whilst providing the required time in vivo.
At present, no single viral vector fulﬁls all the criteria
for use in cardiovascular gene therapy and the advan-
tages/disadvantages of each are summarised in Table 2.
Examples of the therapeutic use of vectors are given in the
relevant section describing cardiovascular disease.
The vast majority of gene transfer studies, not just
those pertaining to cardiovascular diseases, have focussed140 Kate L. Dishart et al 2003:2 (2003)
Table 2. Key features of gene therapy viral vectors.
Viral vectors Integration Long-term gene Immune response Comments
expression
Adenovirus −− +
Broad tropism, easy to produce high titre stocks,
widely characterised in vivo
Adeno-associated
++ − Limited cloning capacity, nonpathogenic, integrate
virus (AAV) randomly in the absence of the rep gene
Lentivirus ++ − Retrovirus-derived, pseudotyping with heterologous
coat proteins improves biosafety
Retrovirus + + − Only infects dividing cells
on the use of adenoviruses. Adenovirus (Ad) is by far the
most commonly applied and well characterised of the ex-
isting viralvectorsfromanexperimentalorclinicalstand-
point. Indeed, of all ongoing gene therapy clinical tri-
als almost 28% can be attributed to Ad-based protocols
withlessthan8%treatingvasculardisorders(http://www.
co.uk/genmed). Ad-mediated gene therapy is dependent
on the level of the coxsackie-adenovirus receptor (CAR)
and integrins (αvβ3 and αvβ5) expressed on the target cell
(Figure 1a). In the context of the cardiovascular system,
Ad infection levels are relatively low when compared to
the hepatic system, however, many successful gene ther-
apy applications have been documented using local de-
livery to target tissue and clinical trials are ongoing [12].
Ad can be produced to a high titer and will infect both
nondividing and dividing cells. However, Ad can result in
a marked inﬂammatory and immunogenic response lim-
iting gene expression, which remains relatively transient
but can be overcome with gutless Ad vectors [15].
Thelastfewy earsha v eseenanincr easeinstudieswith
adeno-associated virus (AAV)-based vectors and conse-
quently AAV has emerged as an important vector system
for gene therapy. rAAV is a replication-defective virus that
is unable to replicate without a helper virus (Figure 1b). It
can be stripped of its viral genes to allow a virus coat that
canbepackagedwithatransgenecassetteofupto4.5kbp.
Unlike other viral vectors, AAV has the ability to integrate
into the genome therefore allowing long-term expression
of the transgene, although in nondividing cells it appears
that rAAV vectors can exist as high-molecular weight epi-
somal DNA [17]. wtAAV integrates stably into chromo-
some 19 [18]h o w e v e r ,r A A Vv e c t o r sd on o ts p e c i ﬁ c a l l y
integrate at this site as rep protein is required to produce
t h i ss i t es pe c i ﬁ c i ty[ 19]. This problem can be overcome by
inserting a truncated rep protein, which allows the rAAV
to restore its ability to integrate at the chromosome 19 site
[20].SingleintramuscularinjectionofAAV-LacZ intoim-
munocompetent mice produced detectable expression for
more than 1.5 years without any evidence of a cellular im-
mune response [21]. The lack of immunogencity of AAV
is an important feature of the vector and gives it a major
advantage over adenoviruses (Table 2).
Nonviralvectors
Ofthecardiovasculartrialsrunningin2001,47%used
either plasmid DNA or liposome carriers [1]. One ap-
proach involves the use of synthetic antisense oligonu-
cleotides, designed to attenuate detrimental proteins [22].
Cis-elementdouble-strandedoligodeoxynucleotides (also
known as decoys) have been employed to modulate gene
expression through the removal of trans-acting factors
from endogenous cis-elements [23]. This is not only a
powerful gene therapy strategy but also enables the study
of endogenous gene regulation both in vitro and in vivo.
For the cardiovascular system, ultrasound can enhance
gene therapy of naked plasmid DNA and has been shown
to increase biological eﬀects of therapeutic genes such as
p53 [24]. Gene transfer of recombinant human VEGF
cDNA in a rabbit model of arterial balloon injury led
to reendothelialization which was 95% complete within
1w e e k[ 25]. In turn, intimal thickening and the occur-
rence of thrombotic occlusion were diminished with an
associated restoration in endothelial cell-dependent va-
somotor reactivity. The treatment of peripheral vascu-
lar disease has seen the intramuscular injection of plas-
mid DNA encoding vascular endothelial growth factor
(VEGF) to increase collateral vessel development and tis-
sue perfusion in the muscle [26]. Importantly, in a clin-
ical trial using ex vivo E2F decoy oligodeoxynucleotide
transfection of human vein grafts, Mann et al [42]h a v e
shown this strategy to reduce proliferation and hence
the occurrence of vein graft occlusion. In addition, no
clinical complications were associated with the proce-
dure.
CARDIOVASCULAR DISEASE TARGETS
FOR GENE THERAPY
Many diseases aﬀecting the cardiovascular system are
amenable to gene therapy protocols. Indeed, success has
been achieved experimentally. Here, we brieﬂy review
the therapeutic strategies relating to the treatment of is-
chaemia, late vein graft failure, atherosclerosis, thrombo-
sis, and hypertension.2003:2 (2003) Gene Therapy for Cardiovascular Disease 141
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Figure 1. (a) Adenoviral (Ad) attachment and internalisation is mediated through the knob protein of the ﬁber binding to CAR,
followed by interaction of the penton base at the base of the ﬁber shaft with αv integrins on the cell surface. Following internalisation,
the virus is localised within cellular endosomes which upon acidiﬁcation allows the virions to escape and traﬃc to the nucleus. Ad-
mediated infection is therefore, dependent on levels of CAR with hepatocytes being highly permissive as shown with reasonable levels
of transduction in endothelial cells (EC). (b) AAV2 binds to the primary receptor heparin sulfate proteoglycan (HSPG) on the cell
surface and internalization is assisted by the secondary receptors αvβ5 integrins and ﬁbroblast growth factor receptor 1. Transduction
of vascular cell, in particular EC, is very poor compared with permissive cell types such as HeLa. Transduction of both cell types with
rAAV2-eGFP clearly shows the diﬀerence in transduction eﬃciency.
Ischaemia
Peripheral ischaemic diseases are commonly associ-
ated with the lower extremities and can be character-
ized by an impaired blood supply resulting from nar-
rowed or blocked arteries, which subsequently starve tis-
sues of the necessary nutrients and oxygen. Similarly, in-
adequate blood ﬂow to the heart gives rise to myocar-
dial ischaemia. This may occur if coronary ﬂow is reduced
by the presence of an atherosclerotic plaque, a blood clot
or an artery spasm. Surgical bypassing and percutaneous
revascularization have alleviated many of the symptoms
but is not suitable for all patients due to the extension of
arterial occlusion and microcirculation impairment. Am-
putation and heart transplants are the only forms of treat-
ment for ischaemia and therefore gene therapy provides
an alternative solution [27, 28]. The two main therapeutic
genes under investigation are the angiogenic growth fac-
tors (VEGF) and ﬁbroblast growth factor (FGF). Research
has focused on delivering these agents to the site of is-
chaemia (Table 1). VEGF is a heparin binding glycopro-
tein, which is a principal angiogenic factor for endothe-
lial cells. The delivery of VEGF to target cells lends it-
self to gene transfer since it is naturally secreted from
cells and therefore can achieve its biological eﬀect with
a limited number of transfected cells (Figure 2). Gow-
dak et al [29] demonstrated that intramuscular injec-
tion of AdVEGF121 resulted in signiﬁcant lengthening of
arterioles and capillaries of nonischaemic limbs in the
rat and rabbit. Furthermore, tissue perfusion in animals
receiving gene delivery two weeks prior to experimen-
tal induction of skeletal muscle ischaemia by removal
of the femoral artery was preserved [29]. Clinically, Ad-
mediated transfer of VEGF has been demonstrated to im-
prove the endothelial function and to lower the extremity
ﬂow reserve in patients with peripheral arterial disease.
In this case, AdVEGF121 was delivered intramuscularly142 Kate L. Dishart et al 2003:2 (2003)
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Figure 2. Angiogenesis in the ischaemic myocardium. Diseased
or injured tissues produce and release angiogenic growth factors
that diﬀuse into nearby tissues. To boost concentration of these
growth factors, such as VEGF, viruses engineered to express one
of the 19 existing angiogenic growth factors can be injected into
the ischaemic area [1]. The angiogenic growth factors bind to
speciﬁc receptors located on the endothelial cells (EC) of nearby
preexisting blood vessels [2]. Activation of EC by VEGF occurs
upon binding to its receptors [3]. Synthesis of new enzymes is
triggered. These enzymes dissolve tiny holes in the sheath-like
covering (basement membrane) surrounding all existing blood
vessels.Theendothelialcellsproliferateandmigrateoutthrough
the dissolved holes of the existing vessel [3]. Extracellular ma-
trix (ECM)-degrading enzymes dissolve the tissue in front of
the sprouting vessel tip [4]. As the vessel extends, the tissue is
remoulded around the vessel and proliferating endothelial cells
roll up to form a blood vessel tube [5]. Blood vessel loops are
formed from individual blood vessel tubes and these are stabi-
lized by the formation of SMC.
and endothelial function determined 30 days postinjec-
tion [30].
In a phase-I clinical trial involving a group of 21 pa-
tients given AdVEGF121 by direct myocardial injection
intotheischaemicregion,noadverseeﬀectsweredetected
locally or systemically. Furthermore, angiography sug-
gested an improvement in the area where the vector
had been delivered and patients described alleviation in
angina symptoms [31]. More recently, the AGENT trial
has addressed the safety and anti-ischaemic eﬀects of ad-
ministering Ad-FGF4 in patients suﬀering from angina.
Single intracoronary infusion of Ad-FGF4 was shown
to result in improved exercise times assessed using the
exercise treadmill test compared to the placebo group
and no adverse side eﬀects [32]. A single intramuscular
injection of AAV-VEGF has been shown in the rat is-
chaemic hindlimb model to produce an increase in cap-
illary growth, a signiﬁcant increase in mean blood ﬂow of
the ischaemic limb, and a higher average skin tempera-
ture [33]. An intracardiac injection of AAV-VEGF165 has
also been shown to induce angiogenesis in the ischaemic
myocardium without any evidence of angioma formation
[34].
Although VEGF has positive eﬀects on the promotion
of angiogenesis, there are pertinent safety considerations.
It has been shown that VEGF may enhance atheroscle-
rotic plaque development through an increase in focal
macrophage levels [35]. Macrophages then induce those
growth factors and cytokines, which mediate intimal hy-
perplasia and contribute to plaque instability through
enhancing levels of matrix metalloproteinases (MMPs)
and other hydrolytic enzymes. Other potential risks of
therapeutic angiogenesis include the production of non-
functional, leaky vessels, and stimulation of angiogene-
sis in tumours [36]. Animal studies in mice highlight the
need for regulated expression of VEGF as persistent un-
regulated VEGF expression following intraventricular in-
jection resulted in the formation of intramural vascular
tumours at the site of myoblast implantation [37]. The
developmentoftissue-speciﬁcvectorsandpromotersmay
help to minimise the risks from these adverse reactions.
Protectionfromreperfusioninjury
Reperfusion of ischaemic myocardium resulting from
dissolution of the blockage by clinical intervention, may
in turn further injure the damaged tissue as a result of
reperfusion injury. Reperfusion leads to oxidative stress in
the tissue and hence may itself require intervention. Hy-
poxic regulatable elements and overexpression of agents,
which scavenge free radicals or reduce oxidative stress,
havebeentargetedusinggenetherapyprotocols(Table 1).
To produce long-term myocardial protection Melo et al
[38] used AAV to deliver the cytoprotective heme oxy-
genase gene by intramyocardial injection into rat hearts.
They found that eight weeks after administration of the
AAV-hHO-1 when acute coronary artery ligation was per-
formed the treated rats had a dramatic reduction in my-
ocardialinfarctionsize[38].Phillipsetal[39]alsodevised
a cardioprotective strategy using a “vigilant vector” AAV
construct.Thisinvolvesaheartspeciﬁcpromoter,MLC2v,
which only expresses mRNA in the heart. The vector also
includes a hypoxia regulatory element (HRE) which can
act as an “on” switch so that production of the trans-
gene antisense AT1R only occurs when ischaemia is de-
tected. This would result in long-term protection of car-
diac function during bouts of ischaemia [39]. In an acute
model of oxidative stress, the eﬀects of expression of su-
peroxide dismutase (SOD) from adenoviral vectors was
investigated [40]. High doses of Ad-SOD3 (3 × 1010 pfu)
resulted in a 3-fold elevation of serum SOD activity
and was protective against hepatic ischaemia-reperfusion
injury.
Lateveingraftfailure
As one of the most commonly performed surgical
procedure at some 400,000 cases worldwide each year,
coronary artery bypass grafts (CABG) are eﬀective at re-
lieving symptoms of angina and prolong life for those pa-
tients with multiple vessel disease. Vein grafts are inserted
into the arterial circulation and undergo a sequence of2003:2 (2003) Gene Therapy for Cardiovascular Disease 143
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Figure 3. Gene therapy by overexpression of TIMP-3. Following Ad-mediated gene delivery to vascular smooth muscle cells, TIMP-3
is secreted and is found located with the extracellular matrix (ECM). From here, TIMP-3 is available to exert two distinctly dif-
ferent phenotypes through its metalloproteinase inhibitory eﬀects. (a) Matrix metalloproteinases (MMPs, including collagenases,
stromelysins, gelatinases, and membrane-type metalloproteinases [MT-MMPs]) are upregulated following vascular injury. TIMPs,
through their native MMP inhibitory activity, are able to bind to and retard pro-MMP-to-active enzyme conversion and combined
with the ability to block active MMP activity, matrix proteolysis and hence cell migration is inhibited [45]. (b) TIMP-3, uniquely
amongst the TIMP family, is also able to promote smooth muscle cell death through death receptor-induced caspase activation and
induction of apoptosis [46]. Micrographs courtesy of Mark Bond, Bristol Heart Institute, UK.
adaptive physiological changes. Early thrombotic occlu-
sion occurs in 10% of grafts with patency rates of 50%
over 10 years due to the onset of intimal thickening and
atheromas [3]. Early thrombosis occurs in the ﬁrst few
weeks after grafting, particularly at the distal anastomosis
due to vessel wall injury. Drug treatments include aspirin
and other antiplatelet agents, which reduce but do not
eliminate early occlusions but are often associated with
hemorrhagic side eﬀects. Late vein graft failure is char-
acterized by progressive medial thickening and neointima
formation. Therefore, vein graft failure limits the clinical
success of coronary bypass grafting in terms of symptoms
and mortality.
Remodelling of the vascular wall by MMPs promotes
SMC migration and proliferation, ultimately leading to
neointima formation and a narrowing of the vessel lu-
men [3]. The main therapeutic targets in the context of
late vein graft failure are those aﬀecting SMC migration
and proliferation. Vein graft lends itself ideally to gene
therapy, as there is a clinical therapeutic window whereby
surgically prepared vein can be genetically modiﬁed prior
to grafting. Many candidate therapeutic target genes have
been studied experimentally with the aim to prevent the
formation of neointimal lesions associated with late vein
graft failure (Table 1) .S M Cp r o l i f e r a t i o na n dm i g r a t i o n
and matrix degradation are integral to lesion formation
and hence, among those classes of gene investigated are
antiproliferative, proapoptotic, antiinﬂammatory, or an-
timigratory agents (for review see [41]).
The PREVENT clinical trial [42] aimed to assess the
eﬃcacy of intraoperative gene therapy in patients receiv-
ingbypassveingrafts.Byblockadingthecelltranscription
factor E2F with decoy oligodeoxynucleoties at the time of
grafting, they were able to signiﬁcantly reduce the inci-
dence of post-operative occlusion. E2F upregulates up to
a dozen cell cycle genes and its inhibition inhibits target
cell cycle gene expression and DNA synthesis. The success
of this trial in reducing bypass graft failure in a high risk
cohort underlines the important role that gene therapy
could play in the prevention of vein graft failure.
MMPs have been shown to be an integral part of
neointima formation, and overexpression of the naturally
occurring tissue inhibitors of MMPs (TIMPs) is a possi-
ble approach. Ad-mediated transfer of TIMPs has been
d e m o n s t r a t e di nan u m b e ro fm o d e l so fv e i ng r a f tf a i l -
ure. In a mouse model, local delivery of Ad-TIMP-2 was
found to reduce vein graft diameter [43]. In contrast, us-
ing the pig saphenous vein-carotid artery interposition
graft model, George et al [46] demonstrated that while
Ad-mediated TIMP-2 delivery was ineﬀective at reduc-
ing vein graft neointima formation, TIMP-3 had a pro-
found inhibitory eﬀect on lesion formation (Figure 3).
This was attributed, in part, to its proapoptotic eﬀect in
the medial and neointimal layers. Encouragingly, the re-
sults from the porcine model were translated into a hu-
man ex vivo model of vein graft failure with an 84% re-
duction in neointima formation following local delivery
of Ad-TIMP-3 [46]. Similarly, TIMP-1 was also shown to144 Kate L. Dishart et al 2003:2 (2003)
haveaninhibitoryeﬀectonlesionformationinthismodel
[47].
Endothelialnitricoxidesynthase(eNOS)isimportant
to vascular homeostasis and plays a vasoprotective role
by inhibiting platelet and leukocyte adhesion, inhibiting
SMC proliferation and migration, and in turn promot-
ing endothelial survival. Local eNOS delivery would, in
theory, arrest the proliferative response to vascular injury.
Nitric oxide (NO) bioactivity is substantially reduced
postbypass graft surgery whilst levels of NO scavenging
superoxide are increased. It is therefore likely that the loss
of NO may contribute to vascular remodelling events in
the vein graft [48]. West et al [49] showed that Ad-nNOS
gene transfer in a rabbit vein graft model favourably af-
fected vein graft remodelling by inhibiting the early in-
ﬂammatorychangesandreducinglateintimalhyperplasia
[49]. They observed an increase in NOS activity, a reduc-
tion in adhesion molecule expression and inﬂammatory
cell inﬁltration, and a reduction in basal superoxide gen-
eration.
Targeting SMC proliferation has also been shown to
be eﬀective using gene therapy protocols. In a rabbit
model of vein grafting, Ad-mediated expression of a con-
stitutively active form of the retinoblastoma gene prod-
uct(Ad∆Rb)reducedneointimaformationfourweeksaf-
ter surgery by 22% [50]. In the human saphenous vein
m o d e lo fv e i ng r a f t ,t a r g e t i n gS M Cb yo v e r e x p r e s s i o no f
wild-type p53 both induced apoptosis and inhibited SMC
migration resulting in a reduction in lesion formation
[51]. Likewise, overexpression of C-type natriuretic pep-
tide, which inhibits SMC growth by Ad resulted in accel-
eratedgraftre-endothelialisationandreducedthrombosis
and neointima formation [52] .K i b b ee ta l[ 53] inhibited
intimal hyperplasia in porcine vein grafts by incubation
with Ad-iNOS for 30 minutes prior to surgery. This eﬀect
was sustained up to 21 days postgrafting [53]. While these
strategies all show short-term eﬀects, long-term studies
are fundamentally important owing to the long-term na-
ture of bypass graft failure.
Thrombosis
Defects in the vessel wall, namely, endothelial cell dys-
function can result in a reduction of antithrombotic ac-
tivity leading to clot formation. The two main groups of
anti-thrombotic genes are those with antiplatelet or anti-
coagulant activity. Prostacylin (PGI2), nitric oxide (NO)
and thrombin inhibitors all act through the inhibition of
platelet adhesion and aggregation, in conjunction with
the prevention of vascular SMC proliferation and vaso-
constriction. The anti-thrombotic treatment, tissue plas-
minogen activator (tPA), which has anticoagulant prop-
erties and is used to lyse existing clots, may be a use-
ful therapeutic gene for antithrombotic therapy (Table 1).
The short half-life of tPA could be overcome with sus-
tained overexpression from a gene therapy vector. Other
anticoagulant gene products include hirudin, thrombo-
modulin, antistasin and, tissue factor pathway inhibitor
(TFPI). Hirudin is perhaps the most potent inhibitor of
thrombin, the enzyme responsible for ﬁbrinogen cleav-
age, platelet activation, and SMC proliferation [54]. The
advantage of local expression of antithrombotic thera-
peutic genes is that not only is thrombolysis promoted
at speciﬁc sites in the artery, but also the side eﬀects of
the conventional anticoagulant are avoided. Clinical con-
ditions amenable to antithrombotic gene therapy include
CABG, percutaneous transluminal coronary angioplasty,
peripheral artery angioplasty, and intravascular stenting.
Intravascular clot formation is a major cause of acute
myocardial infarction and contributes to the majority of
sudden deaths in patients with coronary artery disease.
Successful thrombolysis for acute thrombosis is depen-
dent on prompt treatment and delays in vector admin-
istration and expression of antithrombotic factors sug-
gests that antithrombotic gene therapy is more likely to
play a role in the prevention of reocclusion and chronic
arterial narrowing. Cyclo-oxygenase-1 (COX-1), the rate
limiting enzyme in the synthesis of PGI2,w a so v e r e x -
pressed by local delivery of Ad to porcine carotid arteries
immediately postangioplasty. This was shown to increase
the levels of PGI2 and, in turn, inhibit thrombosis in in-
jured vessels [55]. By manipulating the coagulation cas-
cade integral in thrombus formation, a number of posi-
tive gene therapy studies have been reported. In a rabbit
stasis/injury model of arterial thrombosis, local overex-
pression of thrombomodulin using Ad was assessed. In
addition to reducing thrombosis, the vector did not in-
duce inﬂammatory damage at the site of delivery [56].
Work by the same group targeting tissue-type plasmino-
genactivator(tPA)alsodemonstratedeﬀectiveprevention
of thrombus formation [57]. Local gene transfer of TFPI
into rabbit carotid arteries using an Ad vector prior to
experimental thrombosis induction completely inhibited
the formation of thrombi without aﬀecting systemic co-
agulation status [58]. Similar data were described in the
porcine carotid artery model following local delivery of
Ad-TFPI [59].
Atherosclerosis
Due to the complexity and interplay of genetic and
environmental factors in the development of atheroscle-
rosis, it is unlikely that localized gene therapy will be a
useful approach in the primary prevention of the disease.
Ineﬃcient intravascular gene transfer eﬃciency through
atherosclerotic lesions and lipid-rich atheromas has been
attributed to the very low numbers of transfectable cells
and the high connective tissue content [60]. An exten-
sive list of therapeutic genes exists for the treatment of
atherosclerosis including LDL- or VLDL-receptor gene
transfer to overcome LDL-receptor eﬃciency, a major in-
herited genetic defect and a determinant of atheroscle-
rosis. Patients with defective enzymes vital for lipopro-
tein metabolism such as lipoprotein and hepatic lipases
would beneﬁt from gene transfer of DNA producing the
correct enzymes. A reduction in the level of atherogenic2003:2 (2003) Gene Therapy for Cardiovascular Disease 145
apolipoprotein (apo) B100 is possible after gene trans-
fer of the apoB mRNA editing enzyme, whilst lipoprotein
A could be lowered with synthesis inhibiting ribozymes.
Apolipoprotein AI (apoAI) and lecithin-cholesterol acyl-
transferase (LCAT) are important factors in the removal
of excess cholesterol and the subsequent reduction in the
incidence of atherosclerotic lesions (Table 1). Through in
vitro bicistronic expression of these two genes from AAV
plasmid vectors, it was shown that increased synthesis of
apoAI and LCAT could play a role in reducing atheroscle-
rotic risk [61].
TheapoE−/− transgenicmouseisawell-establishedex-
perimental model for atherosclerosis as it develops severe
hypercholesterolaemia and atherosclerotic lesions similar
to humans. Harris et al (2002) found that they could de-
tect apoE mRNA in the muscle from a single intramus-
cular injection into the apoE−/− mouse, but could not
detect circulating recombinant apoE in the plasma [62].
However circulating antibodies were detected against the
human apoE. The most signiﬁcant ﬁnding of this study
was three months after administration of the AAV-apoE
they found a signiﬁcant reduction (approximately 30%)
in atherosclerotic plague density in the aortas of treated
animals compared to the controls. These results suggest
that only low levels of apoE are required to produce pro-
tection against atherosclerosis.
Attenuation of lesion development has been demon-
strated using Ad-mediated overexpression of heme
oxygenase-1 [63], TIMP-1 [64], platelet-activating factor
acetylhydrolase (PAF-AH)—the enzyme responsible for
the inactivation of PAF [65] and apoE itself, administered
intravenously [66]. Of particular signiﬁcance, Kim et al
[15] recently described the lifetime correction of hyperc-
holesterolaemia in apoE−/− mice following a single intra-
venousinjectionofahelper-dependentAdvector.Follow-
up of 2.5 years old mice demonstrated 100% coverage of
theaortawithatheroscleroticplaquesincontrolmicewith
almost no lesion development in treated animals [15].
Hypertension
Systemic hypertension is a common multifactorial
disorder primarily manifesting itself as chronic high
blood pressure and is a major risk factor for atheroscle-
rosis, peripheral vascular disease stroke, and many other
complications associated with structural damage to the
cardiovascular system. Drugs for controlling high blood
pressure are eﬀective over a 24-hour period, are nonspe-
ciﬁc and cause side eﬀects. It is well established that the
hyperactive renin-angiotensin system (RAS) is a key fac-
tor in primary hypertension and gene therapy strategies
have concentrated on those genes in the RAS controlling
regulation of blood pressure.
Due to its multifactorial nature, gene therapy for hy-
pertension has yet to be demonstrated clinically. Many
gene therapy interventions have, however, been employed
successfullyinthelaboratory(forreview,see[67,68,69]).
Targeting elements involved in the oxidative stress path-
ways (Table 1), Alexander et al [70] and Fennell et al [71]
have demonstrated an improvement of endothelial func-
tion in the SHRSP with local delivery of Ad-eNOS [70]
or Ad-extracellular SOD [71]. Angiotensin II-induced
hypertension and accompanying endothelial dysfunction
were studied by Nakane et al [72]. Gene transfer of Ad-
eNOS but not SOD (copper/zinc or extracellular SOD)
wasshowntorestoreendothelialfunction exvivoinaortic
ringsfromtreatedrabbits[72].Ad-eNOSdeliveryintothe
rostral ventrolateral medulla of SHRSP and WKY rats re-
sulted in a signiﬁcant reduction in blood pressure in both
rats [73]. A continuous supply of tissue kallikrein by a
single intramuscular injection of Ad produced a signif-
icant delay of elevated blood pressure for ﬁve weeks in
the SHR [74]. An increase in vasodilator proteins such as
kallikrein, eNOS, and atrial natriuretic peptide (ANP) in
animal models has correlated with a reduction in blood
pressure [75].
Antisense targeting angiotensinogen and the an-
giotensin type-1 (AT1) receptor attempted to decrease
those genes responsible for vasoconstriction [76]. AAV-
plasmids have been used to deliver antisense AT1-R to
SHR rats [76]. They showed that a single intracardiac in-
jection was suﬃcient to reduce blood pressure by 30mm
Hg when compared to the controls over a ﬁve-week pe-
riod [76]. The eﬀect of AAV-AGT-AS on the development
of hypertension in SHR rats has also been examined. The
rats were injected with AAV-AGT-AS ﬁve days after birth
as the development of hypertension in SHR rats com-
mences between the eighth and tenth week after birth.
A signiﬁcant slowing of the development of hypertension
for six months was observed but there was no complete
inhibition of the rise in blood pressure [77].
THE FUTURE OF GENE THERAPY IN THE TREATMENT
OF CARDIOVASCULAR DISEASE
Due to the complexity of cardiovascular disorders, a
major stumbling block may be the identiﬁcation of the
best gene to treat the disease. It is most likely that a cock-
tail of therapeutic genes rather than a single particular
gene will be the most eﬀective treatment of certain car-
diovascular diseases such as hypertension and atheroscle-
rosis. In order for gene therapy to become a reality in
the cardiovascular clinic, eﬀective therapeutic genes and
suitable vectors must be identiﬁed and developed. Results
from the ﬁrst clinical trials have indicated that vascular
gene transfer is not only safe but may have therapeutic
beneﬁts when administered intravascularly or intramus-
cularly.
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